Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.

Cancer research - 15 Jan 2018

Brighton Hailey E, Angus Steven P, Bo Tao, Roques Jose, Tagliatela Alicia C, Darr David B, Karagoz Kubra, Sciaky Noah, Gatza Michael L, Sharpless Norman E, Johnson Gary L, Bear James E

Abstract excerpt

Targeted therapeutics that are initially effective in cancer patients nearly invariably engender resistance at some stage, an inherent challenge in the use of any molecular-targeted drug in cancer settings. In this study, we evaluated resistance mechanisms arising in metastatic melanoma to MAPK pathway kinase inhibitors as a strategy to identify candidate strategies to limit risks of resistance. To investigate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Longitudinal Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Pyrimidinones

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 29180473
DOI: 10.1158/0008-5472.CAN-17-1653
PMCID: PMC6132242

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.PMID 29180473Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.Semantic proximity Read ↗

Spatiotemporal profiling defines persistence and resistance dynamics during targeted treatment of melanomaSemantic proximity Read ↗

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptationSemantic proximity Read ↗

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapySemantic proximity Read ↗

Dissecting targeted therapy resistance: Integrating models to quantify environment mediated drug resistanceSemantic proximity Read ↗

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanomaSemantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.Semantic proximity Read ↗

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.Semantic proximity Read ↗

Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf -Mutant MelanomaSemantic proximity Read ↗

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.